Commented Articles

PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.

Global Prevalences of NAFLD, NAFL and NASH in the Overweight and Obese Population

Authors: Quek J, En Chan K, Yu Wong Z et al.
Published in The Lancet Gastroenterology and Hepatology 2022
Non-alcoholic fatty liver disease (NAFLD) is currently the fastest-growing indicator for liver transplantation worldwide. Its status as a growing health concern further parallels the global rise of obesity.
Read MoreGlobal Prevalences of NAFLD, NAFL and NASH in the Overweight and Obese Population

NAFLD: A Growing Burden with a Rising Global Prevalence?

Authors: Younossi Z, Golabi P, Paik J et al.
Published in Hepatology 2023
Data from the Global Burden of Disease study indicates that non-alcoholic fatty liver disease (NAFLD) is the most rapidly increasing global contributor to chronic liver disease (CLD)-associated complications, which include the onset of cirrhosis and hepatocellular carcinoma.
Read MoreNAFLD: A Growing Burden with a Rising Global Prevalence?

Effects of Mitochondrial Transplant Therapy on the Reparation of Injured Skeletal Muscle

Authors: Alway SE, Paez HG, Pitzer CR et al.
Published in Journal of Cachexia, Sarcopenia and Muscle 2023
It is known that traumatic muscle injury damages mitochondria, which may cause them to leak their contents into the cytoplasm and subsequently trigger calcium accumulation, cell death, endoplasmic reticulum stress, and the release of reactive oxygen species (ROS).
Read MoreEffects of Mitochondrial Transplant Therapy on the Reparation of Injured Skeletal Muscle

Daily Walking Speed and Frailty: A Significant Association?

Authors: Kawai H, Obuchi S, Ejiri M et al.
Published in BMJ 2023
Walking speed (WS) is clinically recognized as a crucial vital sign. Associations between daily walking speed (DWS) and health outcomes have been underscored by a number of studies, which have further recognized it as an accurate predictor of dependency and mortality in elderly individuals. Despite this knowledge, very few studies have examined the link between DWS and frailty.
Read MoreDaily Walking Speed and Frailty: A Significant Association?

A Multidisciplinary Approach to NAFLD-centred Care

Authors: Schattenberg JM, Allen AM, Jarvis H et al.
Published in Communications Medicine 2022
The association between metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD) has been well-characterised by recent literature. As such, patients with NAFLD are disproportionately affected by a range of comorbidities, which include obesity, dyslipidemia, type 2 diabetes mellitus (T2DM), and hypertension.
Read MoreA Multidisciplinary Approach to NAFLD-centred Care

The FAST Score for Fibrotic NASH: A Useful Non-invasive Tool?

Authors: Ravaioli F, Dajti E, Mantovani A et al.
Published in Gut 2022
A non-invasive combined model termed FibroScan-aspartate aminotransferase (FAST) was recently proposed for the diagnosis of fibrotic non-alcoholic steatohepatitis (NASH). Conceptualised for patients with elevated non-alcoholic fatty liver disease (NAFLD) activity scores (≥4) and significant fibrosis
Read MoreThe FAST Score for Fibrotic NASH: A Useful Non-invasive Tool?

Understanding the clinical benefits of cirrhosis regression in NASH

Authors: Sanyal AJ, Anstee QM, Trauner M et al.
Published in Hepatology 2022
Cirrhosis is the end stage of a number of chronic liver diseases, including non-alcoholic steatohepatitis (NASH). Characterised by the scarring of liver tissue, cirrhosis leads to significant hepatic tissue distortion, which may subsequently cause portal hypertension, hepatic synthetic dysfunction, and hepatocellular carcinoma.
Read MoreUnderstanding the clinical benefits of cirrhosis regression in NASH

NASH: the new fastest growing cause of liver cancer worldwide?

Authors: Huang DQ, Singal AG, Kono Y et al.
Published in Cell Metabolism 2022
Liver cancer has recently been defined as the third leading cause of cancer globally. Although its main aetiologies are hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol, and non-alcoholic steatohepatitis (NASH), the past decade has seen notable shifts in liver disease burden.
Read MoreNASH: the new fastest growing cause of liver cancer worldwide?

Molecular mechanisms of NAFLD: guidance for future pharmacologic treatments

Authors: Che W, Zhao M, Li X, et al.
Published in Frontiers in Endocrinology 2022
The prevalence of non-alcoholic fatty liver disease (NAFLD) is growing in parallel with that of metabolic diseases. NAFLD and metabolic syndrome, which exacerbates the risk of developing type 2 diabetes, have been shown to be heavily interlinked. Despite recent findings regarding NAFLD’s metabolic basis, its molecular basis remains unclear.
Read MoreMolecular mechanisms of NAFLD: guidance for future pharmacologic treatments

Examining exercise’s effect on NAFLD: a systematic review

Authors: Chen G, Banini B, Do A, et al.
Published in Clinical and Molecular Hepatology 2022
No pharmacologic therapies have yet been approved for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), its progressive form. Instead, NAFLD is currently managed by lifestyle interventions, including dietary modifications and physical exercise. Despite this, evidence regarding the effect of exercise on NAFLD-associated histological endpoints is lacking.
Read MoreExamining exercise’s effect on NAFLD: a systematic review

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES